While it waits to hear the fate of Alzheimer's hopeful aducanumab, Biogen, Inc. has switched its neurology focus to ink a deal with Sage Therapeutics, Inc. and bag the rights to two potential blockbusters for major depressive and movement disorders.
The two firms are going to jointly develop and commercialize Sage's zuranolone for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders, plus SAGE-324 for essential tremor and other neurological disorders in the US. The deal is a big one, with Biogen paying Sage almost $1